212 related articles for article (PubMed ID: 20425773)
1. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Zirlik K; Nashan D; Veelken H
Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
[No Abstract] [Full Text] [Related]
2. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
[No Abstract] [Full Text] [Related]
3. Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
Heymann WR
J Am Acad Dermatol; 2008 Oct; 59(4):696-7. PubMed ID: 18793938
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G
Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744
[TBL] [Abstract][Full Text] [Related]
5. Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.
Gardner JM; Evans KG; Goldstein S; Kim EJ; Vittorio CC; Rook AH
Arch Dermatol; 2009 Sep; 145(9):985-8. PubMed ID: 19770436
[No Abstract] [Full Text] [Related]
6. Vorinostat.
Grant S; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
[No Abstract] [Full Text] [Related]
7. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
8. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.
Zain J; Kaminetzky D; O'Connor OA
Expert Rev Hematol; 2010 Apr; 3(2):187-203. PubMed ID: 21083462
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
14. Vorinostat approved for rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
[No Abstract] [Full Text] [Related]
15. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and treatment for cutaneous T-cell lymphomas].
Hamada T; Iwatsuki K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():537-43. PubMed ID: 23134012
[No Abstract] [Full Text] [Related]
17. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
18. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
Thaler F
Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
Giannini G; Cabri W; Fattorusso C; Rodriquez M
Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]